Nektar Therapeutics (NKTR) Common Equity (2010 - 2026)
Nektar Therapeutics (NKTR) posted quarterly Common Equity of $576.2 million for Q1 2026, up 4094.32% year-over-year from $13.7 million in Q1 2025, and up 541.44% quarter-over-quarter from $89.8 million in Q4 2025.
Nektar Therapeutics (NKTR) Common Equity (2010 - 2026) Analysis & Trends
Nektar Therapeutics' Common Equity history runs 17 years deep, the most recent figure standing at $576.2 million for Q1 2026.
- In Q1 2026, Common Equity rose 4094.32% year-over-year to $576.2 million; the TTM figure through Mar 2026 stood at $576.2 million (up 4094.32% YoY), while the FY2025 annual figure was $89.8 million, up 47.9% from the prior year.
- Common Equity for Q1 2026 stood at $576.2 million, up from $89.8 million in the prior quarter.
- The five-year high for Common Equity was $607.9 million in Q1 2022, with the low at -$24.2 million in Q2 2025.
- The 5-year median for Common Equity is $131.0 million (2023), against an average of $213.5 million.
- The sharpest annual moves came in 2025 and 2026: Common Equity tumbled 130.38% in 2025, then surged 4094.32% in 2026.
- Nektar Therapeutics' Common Equity stood at $366.6 million in 2022, then plunged by 64.27% to $131.0 million in 2023, then tumbled by 53.63% to $60.7 million in 2024, then soared by 47.9% to $89.8 million in 2025, then soared by 541.44% to $576.2 million in 2026.
- Business Quant data shows NKTR's Common Equity at $576.2 million in Q1 2026, $89.8 million in Q4 2025, and $85.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Nektar Therapeutics | 1.49 Bn | 919.46 Mn | 3.16 Mn | 576.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 576.22 Mn |
| Dec 31, 2025 | 89.83 Mn |
| Sep 30, 2025 | 85.09 Mn |
| Jun 30, 2025 | -24.21 Mn |
| Mar 31, 2025 | 13.74 Mn |
| Dec 31, 2024 | 60.74 Mn |
| Sep 30, 2024 | 48.88 Mn |
| Jun 30, 2024 | 79.69 Mn |
| Mar 31, 2024 | 126.71 Mn |
| Dec 31, 2023 | 130.99 Mn |
| Sep 30, 2023 | 159.37 Mn |
| Jun 30, 2023 | 196.96 Mn |
| Mar 31, 2023 | 240.87 Mn |
| Dec 31, 2022 | 366.64 Mn |
| Sep 30, 2022 | 412.22 Mn |
| Jun 30, 2022 | 458.73 Mn |
| Mar 31, 2022 | 607.89 Mn |
| Dec 31, 2021 | 679.51 Mn |
| Sep 30, 2021 | 801.54 Mn |
| Jun 30, 2021 | 904.98 Mn |